A Phase Ib/II Study of SHR-A1811 and Fulvestrant in Combination With or Without HS-10352 in Locally Advanced or Metastatic Breast Cancer Patients Who Progressed After Adjuvant Therapy
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Fulvestrant (Primary) ; HS-10352 (Primary) ; Trastuzumab rezetecan (Primary)
 - Indications Advanced breast cancer
 - Focus Adverse reactions; Therapeutic Use
 
Most Recent Events
- 29 Jan 2025 New trial record